Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to TipRanks, Brisebois is a 3-star analyst with an average return of 2.4% and a 40.11% success rate. Brisebois covers the Healthcare sector, focusing on stocks such as Savara, Praxis Precision Medicines, and Opus Genetics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Opus Genetics with a $10.58 average price target.
Based on Opus Genetics’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $2.16 million and a GAAP net loss of $65.54 million. In comparison, last year the company earned a revenue of $4.37 million and had a GAAP net loss of $8.19 million
Based on the recent corporate insider activity of 35 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of IRD in relation to earlier this year. Last month, Robert Gagnon, the CFO of IRD sold 7,842.00 shares for a total of $40,621.56.
